These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1348979)

  • 1. Long-term treatment with the dopamine agonist CV 205-502 of patients with a clinically non-functioning, gonadotroph, or alpha-subunit secreting pituitary adenoma.
    Kwekkeboom DJ; Lamberts SW
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):171-6. PubMed ID: 1348979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma.
    Nobels FR; de Herder WW; van den Brink WM; Kwekkeboom DJ; Hofland LJ; Zuyderwijk J; de Jong FH; Lamberts SW
    Eur J Endocrinol; 2000 Nov; 143(5):615-21. PubMed ID: 11078985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas.
    Andersen M; Bjerre P; Schrøder HD; Edal A; Høilund-Carlsen PF; Pedersen PH; Hagen C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):23-30. PubMed ID: 11167922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of a gonadotrophin-releasing hormone agonist ([D-Ser(But)6]GnRH(1-9)nonapeptide-ethylamide) on gonadotrophin secretion from human pituitary gonadotroph cell adenomas in vitro.
    Daniels M; Newland P; Dunn J; Kendall-Taylor P; White MC
    J Endocrinol; 1988 Sep; 118(3):491-6. PubMed ID: 2460576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal response of luteinizing hormone beta subunit to thyrotrophin-releasing hormone in patients with non-functioning pituitary adenoma.
    Gil-del-Alamo P; Pettersson KS; Saccomanno K; Spada A; Faglia G; Beck-Peccoz P
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):661-6. PubMed ID: 7828356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro.
    de Bruin TW; Kwekkeboom DJ; Van't Verlaat JW; Reubi JC; Krenning EP; Lamberts SW; Croughs RJ
    J Clin Endocrinol Metab; 1992 Nov; 75(5):1310-7. PubMed ID: 1430093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502.
    Vance ML; Lipper M; Klibanski A; Biller BM; Samaan NA; Molitch ME
    Ann Intern Med; 1990 May; 112(9):668-73. PubMed ID: 1970714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responses to gonadotropin releasing hormone agonist and antagonist administration in patients with gonadotroph cell adenomas.
    Chanson P; Lahlou N; Warnet A; Roger M; Sassolas G; Lubetzi J; Schaison G; Bouchard P
    J Endocrinol Invest; 1994 Feb; 17(2):91-8. PubMed ID: 8006338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas.
    Nobels FR; Kwekkeboom DJ; Coopmans W; Hoekstra R; De Herder WW; Bouillon R; Lamberts SW
    J Clin Endocrinol Metab; 1993 Sep; 77(3):784-9. PubMed ID: 7690365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotroph adenoma with secondary hypersecretion of testosterone.
    Chamoun R; Layfield L; Couldwell WT
    World Neurosurg; 2013 Dec; 80(6):900.e7-11. PubMed ID: 23201183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotroph cell adenomas of the pituitary.
    Snyder PJ
    Endocr Rev; 1985; 6(4):552-63. PubMed ID: 2416559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of thyrotropin-releasing hormone test, SMS 201-995, and bromocriptine in the diagnosis and treatment of gonadotropin-secreting pituitary adenomas.
    Blanco C; Lucas T; Alcañiz J; Davila N; Serrano P; Barcelò B; Estrada J
    J Endocrinol Invest; 1994 Feb; 17(2):99-104. PubMed ID: 8006339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gonadotropin-secreting pituitary adenoma with concomitant hypersecretion of testosterone and elevated sperm count. Treatment with LRH agonist.
    Zárate A; Fonseca ME; Mason M; Tapia R; Miranda R; Kovacs K; Schally AV
    Acta Endocrinol (Copenh); 1986 Sep; 113(1):29-34. PubMed ID: 2945349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of hormonal secretory behavior of gonadotroph cell adenomas in vivo and in culture.
    Snyder PJ; Bashey HM; Phillips JL; Gennarelli TA
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1061-5. PubMed ID: 2414310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibin and follicle-stimulating hormone levels in gonadotroph adenomas: evidence of a positive correlation with tumour volume in men.
    Lahlou N; Le Nestour E; Chanson P; Seret-Bégué D; Bouchard P; Roger M; Warnet A
    Clin Endocrinol (Oxf); 1993 Mar; 38(3):301-9. PubMed ID: 8458102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New technique for quantitation of pituitary adenoma size: use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist.
    McGrath GA; Goncalves RJ; Udupa JK; Grossman RI; Pavlou SN; Molitch ME; Rivier J; Vale WW; Snyder PJ
    J Clin Endocrinol Metab; 1993 May; 76(5):1363-8. PubMed ID: 8496331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.